Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilising its precision timed release drug delivery platform technology, announced yesterday that it has named Matthew Brams, MD as its new chief medical officer.

Brams is a co-founder of Cingulate Therapeutics and presently serves as a member of the board of directors. He has been a lead investigator in several pivotal trials involving drugs for the treatment of ADHD, autism, bipolar disorder and schizophrenia. He has extensive experience in drug development and execution of Phase I-IV trials. He has been involved in over 125 clinical trials in adult and paediatric populations in all areas of psychiatry, and has more than 25 years of clinical experience managing patients in the field of Adult and Child Psychiatry with particular expertise in ADHD and Autistic Spectrum Disorders (ASD). Prior to taking the role of CMO at Cingulate, he held the position of medical director and principal of Bayou City Research, Inc where he has been instrumental in gaining FDA approval of over 15 Central Nervous System drugs currently prescribed for use in these patients.

Shane J Schaffer, PharmD, chairman and chief executive officer of Cingulate Therapeutics, said, 'Matt brings a wealth of clinical trial experience to our team as we work to optimise our regulatory plans for our lead product candidates CTX-1301 and CTX-1302.'